274 related articles for article (PubMed ID: 36760515)
1. Emerging therapies in thymic epithelial tumors (Review).
Dapergola A; Gomatou G; Trontzas I; Panagiotou E; Dimakakos E; Syrigos N; Kotteas E
Oncol Lett; 2023 Feb; 25(2):84. PubMed ID: 36760515
[TBL] [Abstract][Full Text] [Related]
2. Update on thymic epithelial tumors: a narrative review.
Cabezón-Gutiérrez L; Pacheco-Barcia V; Carrasco-Valero F; Palka-Kotlowska M; Custodio-Cabello S; Khosravi-Shahi P
Mediastinum; 2024; 8():33. PubMed ID: 38881809
[TBL] [Abstract][Full Text] [Related]
3. Thymic Epithelial Tumor and Immune System: The Role of Immunotherapy.
Perrino M; Cordua N; De Vincenzo F; Borea F; Aliprandi M; Cecchi LG; Fazio R; Airoldi M; Santoro A; Zucali PA
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067278
[TBL] [Abstract][Full Text] [Related]
4. Fatal toxicity induced by anti-PD-1 immune checkpoint inhibitor in thymic epithelial tumor.
Jing X; Zhu H; Li Y; Jia W; Zhai X; Li J; Yu J
Immunotherapy; 2022 Oct; 14(14):1097-1107. PubMed ID: 36093721
[TBL] [Abstract][Full Text] [Related]
5. What Have We Learned from Molecularly Informed Clinical Trials on Thymomas and Thymic Carcinomas-Current Status and Future Directions?
Maniar R; Loehrer PJ
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254905
[TBL] [Abstract][Full Text] [Related]
6. Understanding the landscape of immunotherapy in thymic epithelial tumors.
Maniar R; Loehrer PJ
Cancer; 2023 Apr; 129(8):1162-1172. PubMed ID: 36808725
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for Management of Thymic Epithelial Tumors: A Double-Edged Sword.
Ballman M; Zhao C; McAdams MJ; Rajan A
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565190
[TBL] [Abstract][Full Text] [Related]
8. Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors.
Tateo V; Manuzzi L; De Giglio A; Parisi C; Lamberti G; Campana D; Pantaleo MA
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260538
[TBL] [Abstract][Full Text] [Related]
9. Evolving treatment landscape in thymic epithelial tumors: From mechanism to therapy.
Yang Y; Yu Y; Fan Y; Li H
Biochim Biophys Acta Rev Cancer; 2024 Jun; 1879(5):189145. PubMed ID: 38942215
[TBL] [Abstract][Full Text] [Related]
10. Narrative review of immunotherapy in thymic malignancies.
Benitez JC; Besse B
Transl Lung Cancer Res; 2021 Jun; 10(6):3001-3013. PubMed ID: 34295693
[TBL] [Abstract][Full Text] [Related]
11. Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors.
Sun TY; Nguyen B; Chen SB; Natkunam Y; Padda S; van de Rijn M; West R; Neal JW; Wakelee H; Riess JW
JTO Clin Res Rep; 2023 Apr; 4(4):100498. PubMed ID: 37020927
[TBL] [Abstract][Full Text] [Related]
12. Molecular landscape of thymic epithelial tumors.
Prays J; Ortiz-Villalón C
Semin Diagn Pathol; 2022 Mar; 39(2):131-136. PubMed ID: 34272124
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of immunotherapy in thymic epithelial tumors: more effective, more risky: a systematic review.
Song X; Fan J; Zhu L; Wang Z; He Y; Zhou C
J Thorac Dis; 2021 Aug; 13(8):5093-5103. PubMed ID: 34527346
[TBL] [Abstract][Full Text] [Related]
14. Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies.
Lippner EA; Lewis DB; Robinson WH; Katsumoto TR
Curr Treat Options Oncol; 2019 Jun; 20(7):62. PubMed ID: 31227926
[TBL] [Abstract][Full Text] [Related]
15. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD
PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603
[TBL] [Abstract][Full Text] [Related]
16. Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in
Szpechcinski A; Szolkowska M; Winiarski S; Lechowicz U; Wisniewski P; Knetki-Wroblewska M
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884448
[TBL] [Abstract][Full Text] [Related]
17. Thymic tumors and immune checkpoint inhibitors.
Yokoyama S; Miyoshi H
J Thorac Dis; 2018 May; 10(Suppl 13):S1509-S1515. PubMed ID: 29951302
[TBL] [Abstract][Full Text] [Related]
18. Epigenetics of Thymic Epithelial Tumors.
Nicolì V; Coppedè F
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672310
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the tumor microenvironment and mutation burden identifies prognostic features in thymic epithelial tumors.
Hou X; Lin S; Liu Y; Wang K; Yu Z; Jia J; Yu J; Zheng W; Bai J; Chang L; Chen J; Li M; Chen L
Am J Cancer Res; 2022; 12(5):2387-2396. PubMed ID: 35693087
[TBL] [Abstract][Full Text] [Related]
20. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G
Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
